Bio-Techne (TECH) Return on Capital Employed (2010 - 2026)
Bio-Techne's quarterly Return on Capital Employed came in at 6.45% in Q1 2026, down 46.0% year-on-year from 11.95% in Q1 2025, and up 31.49% quarter-over-quarter from 4.91% in Q4 2025.
Bio-Techne has reported Return on Capital Employed for 17 years, with the latest figure at 6.45% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 46.0% year-over-year to 6.45%; the trailing twelve-month figure through Mar 2026 stood at 6.45% (down 46.0% YoY), and the FY2025 full-year result was 4.17%, down 406.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 6.45%, up from 4.91% in the prior quarter.
- The five-year high for Return on Capital Employed was 13.98% in Q2 2022, with the low at 4.22% in Q2 2025.
- Average Return on Capital Employed over 5 years is 9.43%, with a median of 9.91% recorded in 2024.
- Year-over-year, Return on Capital Employed jumped 260 bps in 2022 and tumbled 422 bps in 2024.
- Tracing TECH's Return on Capital Employed over 5 years: stood at 13.25% in 2022, then retreated by 22 bps to 10.3% in 2023, then retreated by 24 bps to 7.88% in 2024, then plunged by 38 bps to 4.91% in 2025, then surged by 31 bps to 6.45% in 2026.
- The last three Return on Capital Employed figures came in at 6.45% (Q1 2026), 4.91% (Q4 2025), and 4.59% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn | 6.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.45% |
| Dec 31, 2025 | 4.91% |
| Sep 30, 2025 | 4.59% |
| Jun 30, 2025 | 4.22% |
| Mar 31, 2025 | 6.91% |
| Dec 31, 2024 | 7.88% |
| Sep 30, 2024 | 7.40% |
| Jun 30, 2024 | 8.10% |
| Mar 31, 2024 | 9.91% |
| Dec 31, 2023 | 10.30% |
| Sep 30, 2023 | 11.62% |
| Jun 30, 2023 | 12.00% |
| Mar 31, 2023 | 12.18% |
| Dec 31, 2022 | 13.25% |
| Sep 30, 2022 | 13.26% |
| Jun 30, 2022 | 13.98% |
| Mar 31, 2022 | 13.33% |
| Dec 31, 2021 | 12.32% |
| Sep 30, 2021 | 11.79% |
| Jun 30, 2021 | 11.74% |
| Mar 31, 2021 | 10.73% |
| Dec 31, 2020 | 9.63% |
| Sep 30, 2020 | 8.95% |
| Jun 30, 2020 | 8.26% |
| Mar 31, 2020 | 8.52% |
| Dec 31, 2019 | 8.49% |
| Sep 30, 2019 | 8.49% |
| Jun 30, 2019 | 8.26% |
| Mar 31, 2019 | 8.31% |
| Dec 31, 2018 | 8.21% |
| Sep 30, 2018 | 8.24% |
| Jun 30, 2018 | 8.92% |
| Mar 31, 2018 | 8.80% |
| Dec 31, 2017 | 8.65% |
| Sep 30, 2017 | 8.18% |
| Jun 30, 2017 | 8.55% |
| Mar 31, 2017 | 8.71% |
| Dec 31, 2016 | 9.34% |
| Sep 30, 2016 | 12.23% |
| Jun 30, 2016 | 14.05% |
| Mar 31, 2016 | 13.73% |
| Dec 31, 2015 | 13.18% |
| Sep 30, 2015 | 13.59% |
| Jun 30, 2015 | 14.08% |
| Mar 31, 2015 | 13.80% |
| Dec 31, 2014 | 15.07% |
| Sep 30, 2014 | 17.29% |
| Jun 30, 2014 | 19.48% |
| Mar 31, 2014 | 7.38% |
| Dec 31, 2013 | 7.37% |
| Sep 30, 2013 | 7.62% |
| Jun 30, 2013 | 7.63% |
| Mar 31, 2013 | 22.52% |
| Dec 31, 2012 | 23.27% |
| Sep 30, 2012 | 23.53% |
| Jun 30, 2012 | 24.96% |
| Mar 31, 2012 | 26.88% |
| Dec 31, 2011 | 27.11% |
| Sep 30, 2011 | 27.75% |
| Jun 30, 2011 | 28.01% |
| Mar 31, 2011 | 10.46% |
| Dec 31, 2010 | 10.25% |
| Sep 30, 2010 | 10.51% |